Citing lack of robust trial data, the committee offers algorithms and advice on care considerations in premenopausal ...

Much of the onus for creating change should fall to the device and pharmaceutical companies themselves, one expert says.

NEW ORLEANS, LA—Adding the factor XIa inhibitor asundexian (Bayer) to antiplatelet therapy tops antiplatelet therapy alone for preventing ischemic strokes in patients with acute noncardioembolic ...

Those with preserved EF seemed to get more protection against HF events/CV death than those with reduced or unknown EF.

With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.

Overcoming clinical inertia around starting and intensifying antihypertensive drugs is key, a researcher says.

It’s a known problem, but treatment hasn’t improved in 20 years. Experts say it’s time for protocolized systems of care, they ...

A bundle of protocols including patient education, skin prep, and glove changes reduced infections at a large US surgical ...

The mechanism remains unclear, but GLP-1 users had less MACE, CV death, and all-cause death driven by fewer amputations.

Neither stenting nor endarterectomy provided a boost versus medical therapy alone in patients with asymptomatic stenosis.

Observational data point to the scope of opportunity that lies in GLP-1 drugs, SGLT2 inhibitors, and nonsteroidal MRAs.